503A or 503B? How the two federal compounding pathways differ — and why it mattered for GLP-1 medicines
Federal law gives compounders two routes, with different rules on prescriptions, quality standards, oversight and copies of approved drugs. Here is how they compare, using GLP-1 compounding as the worked example.
The signal
Federal law recognizes two compounding pathways: section 503A, for state-licensed pharmacies and physicians compounding for identified patients, and section 503B, for registered outsourcing facilities that must meet current good manufacturing practice requirements.
Why this matters
The pathway determines whether a patient-specific prescription is needed, which quality requirements apply, how FDA oversees the compounder and when copies of approved drugs may be made — the questions at the center of GLP-1 compounding as those medicines moved onto and off FDA’s drug shortage list.
The 2-minute brief
Section 503A is the traditional pharmacy-compounding pathway: a licensed pharmacist or physician compounds for an identified patient on a valid prescription, and the drug can be exempt from FDA approval, CGMP and some labeling requirements when the section’s conditions are met.
Section 503B, added in 2013, created outsourcing facilities. They register with FDA, must follow CGMP, are inspected by FDA and report adverse events and products — and they may supply compounded drugs in response to orders from health care providers, without patient-specific prescriptions.
For GLP-1 medicines the difference became practical when FDA’s drug shortage list changed. Both pathways restrict copies of approved drugs, but the restrictions relax while a drug is in shortage and return when FDA resolves the shortage, as FDA has determined for tirzepatide and semaglutide injection products.
What changed
- Section 503A covers compounding by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a licensed physician, and requires that drugs be compounded on the basis of valid patient-specific prescriptions.[1]
- When its conditions are met, section 503A exempts compounded drugs from FDA approval, current good manufacturing practice (CGMP) requirements and the requirement for adequate directions for use.[1]
- Section 503B, created by the Drug Quality and Security Act in 2013, established outsourcing facilities: compounders of sterile drugs that register with FDA.[1, 2]
- Outsourcing facilities must comply with CGMP requirements, are inspected by FDA on a risk-based schedule, report adverse events and give FDA information about the products they compound.[2]
- An outsourcing facility may distribute compounded drugs pursuant to a patient-specific prescription or in response to an order from a health care provider, and is not required to be a licensed pharmacy.[1, 3]
- Both pathways limit compounding drugs that are essentially copies of approved or commercially available drugs, and those limits work differently while a drug is on FDA’s drug shortage list.[4]
- FDA has determined that the shortages of tirzepatide injection and semaglutide injection products are resolved.[5]
- Compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness or quality before they are marketed.[6]
Who this affects
- 503A compounders
- 503B outsourcing facilities
- Pharmacies
- Pharmacists
- Prescribers
- Weight-management clinics
- Med spas
What to watch next
FDA statements on GLP-1 compounding and changes to the drug shortage list, which determine when shortage-related flexibilities apply.[5]
FDA decisions on which bulk drug substances outsourcing facilities may use.[3]
Full analysis
Who can compound under each pathway
Section 503A applies to licensed pharmacists in state-licensed pharmacies or federal facilities, and to licensed physicians. Section 503B applies to outsourcing facilities: facilities at one geographic location that compound sterile drugs, have elected to register with FDA and comply with all of section 503B. An outsourcing facility does not have to be a licensed pharmacy, but its compounding must be done by or under the direct supervision of a licensed pharmacist.
Prescriptions and orders
503A compounding is tied to valid patient-specific prescriptions. Outsourcing facilities may distribute compounded drugs pursuant to a prescription or in response to an order from a health care provider, which lets them supply facilities before individual prescriptions exist.
Quality standards and oversight
Compounders that meet the conditions of section 503A are exempt from federal CGMP requirements and are overseen mainly by state boards of pharmacy. Outsourcing facilities must comply with CGMP, are inspected by FDA on a risk-based schedule, and must report adverse events and the products they compound.
Copies of approved drugs and the shortage list
Under section 503A, a compounder may not regularly or in inordinate amounts compound drugs that are essentially copies of a commercially available drug product — but FDA does not consider a drug commercially available while it is on its drug shortage list. Under section 503B, outsourcing facilities may not compound essentially copies of approved drugs unless the approved drug is on the shortage list, and may use bulk drug substances only if the substance is on FDA’s 503B bulks list or the drug is on the shortage list.
What this means in practice
- Confirm which pathway a compounded product was made under.
- Check the drug’s current status in FDA’s Drug Shortages database rather than relying on older statements.
- Remember that compounded drugs are not FDA-approved, and that state law can add requirements.
NPHLA takeaway
The legal pathway, not the product name, decides the rules. Before relying on a compounded GLP-1 product, pharmacies, prescribers and clinics should confirm whether it was made under section 503A or 503B and check FDA’s current shortage status and statements. This is general information, not legal advice.
Source file
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
Drafted with AI assistance from the sources listed in the Source File, then reviewed and approved by an NPHLA editor before publication. NPHLA links to sources and does not republish their text. Professional information only — not medical, legal or regulatory advice for any individual situation. Our standards.